Trials Sponsors Conditions Drugs Pricing

Conditions

Assisted Reproductive Treatments Gonadotropin Releasing Hormone Antagonist Protocol Progesterone Primed Endometrial Protocol

Outcome Measures

Primary Outcomes (1)

The number of retrieved oocytes
Retrieved oocytes will be collected after ovarian induction by gonadotropin injection
34 to 36 hours post HCG administration

Secondary Outcomes (1)

Pregnancy rate
Fourteen days following the transfer

Study Arms (2)

Progesterone primed endometrial protocol

ACTIVE COMPARATOR

The cases were received soft progesterone capsules (brand name: Utrogestan, 100 mg, Laboratories Besins International, France) 100 mg and 150 IU of human menopausal gonadotropin (hMG) concomitantly from the menstrual cycle (MC) day 3 until the trigger day

Other: Progesterone primed endometrial protocol

Gonadotropin-releasing hormone antagonist protocol

EXPERIMENTAL

The cases were received the gonadotropin-releasing hormone antagonist (GnRH-ant) protocol consisting of HMG 150 IU's daily injection from MC 3 until the trigger day. GnRH-ant (Cetrotide, 0.25 mg, MerckSerono) was started when at least one of the following criteria were met: LH \>10 IU/L, the presence of at least one follicle with mean diameter \>14 mm, or serum E2 level \>600 pg/mL.

Other: Gonadotropin-releasing hormone antagonist protocol

Interventions

Progesterone primed endometrial protocolOther

Progesterone primed endometrial protocol

Gonadotropin-releasing hormone antagonist protocolOther

Eligibility Criteria

Age21 Years - 40 Years

Sexfemale(Gender-based eligibility)

Gender Eligibility DetailsWomen undergoing IVF/ICSI cycles with ages of 21 to 40 years, body mass index between 18.5 to 29.9 kg/m2, with previous poor response to conventional prolonged therapy utilizing GnRH agonists (retrieving three oocytes), along with a basal antral follicle count of less than six. .

Healthy VolunteersNo

Age GroupsAdult (18-64)

You may qualify if:

Age 21 to 40 years.

Sponsors & Collaborators

New Valley University
Otherlead

Study Sites (1)

New Valley University

New Valley, New Valley Governorate, 72511, Egypt

Enrollment

40 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Lecturer of Obstetrics and Gynecology, Faculty of Medicine, New Valley University.

Study Record Dates

First Submitted

February 22, 2024

First Posted

March 7, 2024

Study Start

September 1, 2022

Actual (reported)

Progesterone Primed Endometrial Protocol Versus Gonadotropin-releasing Hormone Antagonist Protocol in Assisted Reproductive Treatments

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (2)

Progesterone primed endometrial protocol

Gonadotropin-releasing hormone antagonist protocol

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (2)

Progesterone primed endometrial protocol

Gonadotropin-releasing hormone antagonist protocol

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations